NASDAQ · USD

Drugs Made In America Acquisition II Corp. (DMIIR) Stock Analysis

Drugs Made In America Acquisition II Corp. (DMIIR) is a stock listed on NASDAQ and quoted in US Dollar.

DMIIR

$0.08

+$0.01 (+14.14%)

Sep 4, 2026 · Market close

This is a derivative instrument — a right to Drugs Made In America Acquisition II Corp. (DMII) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View DMII →

Price History

Hover for the daily close. The dotted line marks the period open.

DMIIR Key Statistics

As of Sep 4, 2026

Trading

Open: $0.08
Previous Close: $0.07
Day's Range: 0.08–0.08
52-Week Range: 0.08–0.08
Volume: 449

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMIIR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−33.42%
2025 (partial year)	+0.00%

As of September 4, 2026.

About Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.